VIROLOGIC RESPONSE TO NEW NUCLEOSIDE REGIMENS AFTER PROLONGED ZDV OR DDI IN HIV

HIV 长期 ZDV 或 DDI 后对新核苷治疗方案的病毒学反应

• 批准号: 6113831
• 负责人: Joseph J Eron
• 金额: $ 1.58万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113831
• 关键词: 2'3' dideoxyinosine; AIDS therapy; HIV infections; antiAIDS agent; clinical research; clinical trials; drug resistance; human immunodeficiency virus; human subject; human therapy evaluation; lamivudine; nucleoside analog; stavudine; virus RNA; zidovudine

ACTG 302 - The purpose of the study is to determine the influence of HIV virius load, characteristics of the virus and the presence of symptoms on response to new therapeutic regimens and on the development of ciral resistance mutation in HIV infected individuals who have been treated with monotherapy with either ZDV or ddI on a previous ACTG trial (ACTG 175). More specifically, this study will determine whether the addition of 3TC or a change to d4T in patients who have been ZDV result in a more rapid or durable suppression of plasma viral RNA.

ACTG 302 - 研究的目的是确定 HIV 的影响 病毒载量、病毒特征和症状的存在 对新治疗方案的反应和循环疗法的发展 接受治疗的艾滋病毒感染者出现耐药性突变 在之前的 ACTG 试验中使用 ZDV 或 ddI 单一疗法（ACTG 175）。 更具体地说，本研究将确定是否添加 在接受过 ZDV 治疗的患者中，使用 3TC 或改为 d4T 会导致更多的结果 快速或持久抑制血浆病毒RNA。